The Potential of MicroRNAs as Prostate Cancer Biomarkers

European Urology

Volumn 70, Issue 2, 2016, Pages 312-322

  Fabris, Linda ^a   Ceder, Yvonne ^b   Chinnaiyan, Arul M ^c   Jenster, Guido W ^d   Sorensen, Karina D ^e   Tomlins, Scott ^c   Visakorpi, Tapio ^f   Calin, George A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Cancer biomarker; Diagnosis; microRNA; Prognosis; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; MESSENGER RNA; MICRORNA; TUMOR MARKER;

BIOCHEMICAL RECURRENCE; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; COHORT ANALYSIS; EARLY DIAGNOSIS; GENE EXPRESSION PROFILING; HUMAN; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; RNA DEGRADATION; TREATMENT RESPONSE; CLASSIFICATION; DISEASE EXACERBATION; DISEASE MANAGEMENT; GENETICS; MALE; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR;

BIOMARKERS, TUMOR; DISEASE MANAGEMENT; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; HUMANS; MALE; MICRORNAS; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 84956950750     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.12.054     Document Type: Review

References (74)

1. [1] Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49 (2013), 1374–1403.
2. [2] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2015. CA Cancer J Clin 65 (2015), 5–29.
3. [3] Cooperberg, M.R., Broering, J.M., Litwin, M.S., et al. CapSURE Investigators. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 171 (2004), 1393–1401.
4. [4] Schroder, F.H., Hugosson, J., Roobol, M.J., et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384 (2014), 2027–2035.
5. [5] Dall'Era, M.A., Cooperberg, M.R., Chan, J.M., et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 112 (2008), 1650–1659.
6. [6] Fraser, M., Berlin, A., Bristow, R.G., van der Kwast, T., Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. Urol Oncol 33 (2015), 85–94.
7. [7] Ambros, V., The functions of animal microRNAs. Nature 431 (2004), 350–355.
8. [8] Valinezhad Orang, A., Safaralizadeh, R., Kazemzadeh-Bavili, M., Mechanisms of miRNA-mediated gene regulation from common downregulation to mRNA-specific upregulation. Int J Genomics, 2014, 2014, 970607.
9. [9] Orom, U.A., Nielsen, F.C., Lund, A.H., MicroRNA-10a binds the 5’UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell 30 (2008), 460–471.
10. [10] Vasudevan, S., Tong, Y., Steitz, J.A., Switching from repression to activation: microRNAs can up-regulate translation. Science 318 (2007), 1931–1934.
11. [11] Jansson, M.D., Lund, A.H., MicroRNA and cancer. Mol Oncol 6 (2012), 590–610.
12. [12] Rauhala, H.E., Jalava, S.E., Isotalo, J., et al. miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int J Cancer 127 (2010), 1363–1372.
13. [13] Calin, G.A., Sevignani, C., Dumitru, C.D., et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 101 (2004), 2999–3004.
14. [14] Cho, W.C., MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol 42 (2010), 1273–1281.
15. [15] Kim, W.T., Kim, W.J., MicroRNAs in prostate cancer. Prostate Int 1 (2013), 3–9.
16. [16] Fang, Y.X., Gao, W.Q., Roles of microRNAs during prostatic tumorigenesis and tumor progression. Oncogene 33 (2014), 135–147.
17. [17] Kristensen, H., Haldrup, C., Strand, S., et al. Hypermethylation of the GABRE∼miR-452∼miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy. Clin Cancer Res 20 (2014), 2169–2181.
18. [18] Song, C., Chen, H., Wang, T., Zhang, W., Ru, G., Lang, J., Expression profile analysis of microRNAs in prostate cancer by next-generation sequencing. Prostate 75 (2015), 500–516.
19. [19] Lan, H., Lu, H., Wang, X., Jin, H., MicroRNAs as potential biomarkers in cancer: opportunities and challenges. BioMed Res Int, 2015, 2015, 125094.
20. [20] Chen, X., Ba, Y., Ma, L., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18 (2008), 997–1006.
21. [21] Cortez, M.A., Bueso-Ramos, C., Ferdin, J., Lopez-Berestein, G., Sood, A.K., Calin, G.A., MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol 8 (2011), 467–477.
22. [22] Schwarzenbach, H., Machado da Silva, A., Calin, G., Pantel, K., Data normalization strategies for microRNA quantification. Clin Chem 61 (2015), 1333–1342.
23. [23] Mall, C., Rocke, D.M., Durbin-Johnson, B., Weiss, R.H., Stability of miRNA in human urine supports its biomarker potential. Biomark Med 7 (2013), 623–631.
24. [24] Volinia, S., Calin, G.A., Liu, C.G., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103 (2006), 2257–2261.
25. [25] Ambs, S., Prueitt, R.L., Yi, M., et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68 (2008), 6162–6170.
26. [26] Porkka, K.P., Pfeiffer, M.J., Waltering, K.K., Vessella, R.L., Tammela, T.L., Visakorpi, T., MicroRNA expression profiling in prostate cancer. Cancer Res 67 (2007), 6130–6135.
27. [27] Ozen, M., Creighton, C.J., Ozdemir, M., Ittmann, M., Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27 (2008), 1788–1793.
28. [28] Moltzahn, F., Olshen, A.B., Baehner, L., et al. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res 71 (2011), 550–560.
29. [29] Bryant, R.J., Pawlowski, T., Catto, J.W., et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 106 (2012), 768–774.
30. [30] Chen, Z.H., Zhang, G.L., Li, H.R., et al. A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate 72 (2012), 1443–1452.
31. [31] Yaman Agaoglu, F., Kovancilar, M., Dizdar, Y., et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol 32 (2011), 583–588.
32. [32] Brase, J.C., Johannes, M., Schlomm, T., et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 128 (2011), 608–616.
33. [33] Haldrup, C., Kosaka, N., Ochiya, T., et al. Profiling of circulating microRNAs for prostate cancer biomarker discovery. Drug Deliv Transl Res 4 (2014), 19–30.
34. [34] Kachakova, D., Mitkova, A., Popov, E., et al. Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer. DNA Cell Biol 34 (2015), 189–200.
35. [35] Huang, X., Yuan, T., Liang, M., et al. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol 67 (2015), 33–41.
36. [36] Corcoran, C., Rani, S., O'Driscoll, L., miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. Prostate 74 (2014), 1320–1334.
37. [37] Korzeniewski, N., Tosev, G., Pahernik, S., Hadaschik, B., Hohenfellner, M., Duensing, S., Identification of cell-free microRNAs in the urine of patients with prostate cancer. Urol Oncol, 33, 2015 16.e7–e22.
38. [38] Haj-Ahmad, T.A., Abdalla, M.A., Haj-Ahmad, Y., Potential urinary miRNA biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients. J Cancer 5 (2014), 182–191.
39. [39] Heidenreich, A., Bastian, P.J., Bellmunt, J., et al. EAU guidelines on prostate cancer Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65 (2014), 467–479.
40. [40] Tong, A.W., Fulgham, P., Jay, C., et al. MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther 16 (2009), 206–216.
41. [41] Schaefer, A., Jung, M., Mollenkopf, H.J., et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 126 (2010), 1166–1176.
42. [42] Haflidadottir, B.S., Larne, O., Martin, M., et al. Upregulation of miR-96 enhances cellular proliferation of prostate cancer cells through FOXO1. PloS One, 8, 2013, e72400.
43. [43] Mortensen, M.M., Hoyer, S., Orntoft, T.F., Sorensen, K.D., Dyrskjot, L., Borre, M., High miR-449b expression in prostate cancer is associated with biochemical recurrence after radical prostatectomy. BMC Cancer, 14, 2014, 859.
44. [44] Leite, K.R., Reis, S.T., Viana, N., et al. Controlling RECK miR21 promotes tumor cell invasion and is related to biochemical recurrence in prostate cancer. J Cancer 6 (2015), 292–301.
45. [45] Li, T., Li, R.S., Li, Y.H., et al. miR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer. J Urol 187 (2012), 1466–1472.
46. [46] Melbo-Jorgensen, C., Ness, N., Andersen, S., et al. Stromal expression of MiR-21 predicts biochemical failure in prostate cancer patients with Gleason score 6. PloS One, 9, 2014, e113039.
47. [47] Selcuklu, S.D., Donoghue, M.T., Spillane, C., miR-21 as a key regulator of oncogenic processes. Biochem Soc Trans 37 (2009), 918–925.
48. [48] Bell, E.H., Kirste, S., Fleming, J.L., et al. A novel miRNA-based predictive model for biochemical failure following post-prostatectomy salvage radiation therapy. PloS One, 10, 2015, e0118745.
49. [49] Martens-Uzunova, E.S., Jalava, S.E., Dits, N.F., et al. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene 31 (2012), 978–991.
50. [50] Larne, O., Martens-Uzunova, E., Hagman, Z., et al. miQ-a novel microRNA based diagnostic and prognostic tool for prostate cancer. Int J Cancer 132 (2013), 2867–2875.
51. [51] Zheng, Q., Peskoe, S.B., Ribas, J., et al. Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy. Prostate 74 (2014), 1655–1662.
52. [52] Ribas, J., Ni, X., Haffner, M., et al. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 69 (2009), 7165–7169.
53. [53] Shen, J., Hruby, G.W., McKiernan, J.M., et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate 72 (2012), 1469–1477.
54. [54] Sun, T., Yang, M., Chen, S., et al. The altered expression of miR-221/-222 and miR-23b/-27b is associated with the development of human castration resistant prostate cancer. Prostate 72 (2012), 1093–1103.
55. [55] Jalava, S.E., Urbanucci, A., Latonen, L., et al. Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. Oncogene 31 (2012), 4460–4471.
56. [56] Ostling, P., Leivonen, S.K., Aakula, A., et al. Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res 71 (2011), 1956–1967.
57. [57] ChunJiao, S., Huan, C., ChaoYang, X., GuoMei, R., Uncovering the roles of miRNAs and their relationship with androgen receptor in prostate cancer. IUBMB Life 66 (2014), 379–386.
58. [58] Spahn, M., Kneitz, S., Scholz, C.J., et al. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 127 (2010), 394–403.
59. [59] Kneitz, B., Krebs, M., Kalogirou, C., et al. Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. Cancer Res 74 (2014), 2591–2603.
60. [60] Goto, Y., Kojima, S., Nishikawa, R., et al. The microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancer. Oncotarget 5 (2014), 7748–7759.
61. [61] Ishteiwy, R.A., Ward, T.M., Dykxhoorn, D.M., Burnstein, K.L., The microRNA -23b/-27b cluster suppresses the metastatic phenotype of castration-resistant prostate cancer cells. PloS One, 7, 2012, e52106.
62. [62] Keller, S., Sanderson, M.P., Stoeck, A., Altevogt, P., Exosomes: from biogenesis and secretion to biological function. Immunol Lett 107 (2006), 102–108.
63. [63] Loblaw, D.A., Walker-Dilks, C., Winquist, E., Hotte, S.J., Genitourinary Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review. Clin Oncol (R Coll Radiol) 25 (2013), 406–430.
64. [64] Josson, S., Sung, S.Y., Lao, K., Chung, L.W., Johnstone, P.A., Radiation modulation of microRNA in prostate cancer cell lines. Prostate 68 (2008), 1599–1606.
65. [65] Li, B., Shi, X.B., Nori, D., et al. Down-regulation of microRNA 106b is involved in p21-mediated cell cycle arrest in response to radiation in prostate cancer cells. Prostate 71 (2011), 567–574.
66. [66] Hatano, K., Kumar, B., Zhang, Y., et al. A functional screen identifies miRNAs that inhibit DNA repair and sensitize prostate cancer cells to ionizing radiation. Nucleic Acids Res 43 (2015), 4075–4086.
67. [67] Tannock, I.F., de Wit, R., Berry, W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004), 1502–1512.
68. [68] Zhang, H.L., Yang, L.F., Zhu, Y., et al. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 71 (2011), 326–331.
69. [69] Lin, H.M., Castillo, L., Mahon, K.L., et al. Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. Br J Cancer 110 (2014), 2462–2471.
70. [70] Kojima, K., Fujita, Y., Nozawa, Y., Deguchi, T., Ito, M., MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 70 (2010), 1501–1512.
71. [71] Liang, J., Li, Y., Daniels, G., et al. LEF1 targeting EMT in prostate cancer invasion is regulated by miR-34a. Mol Cancer Res 13 (2015), 681–688.
72. [72] Cheng, C.Y., Hwang, C.I., Corney, D.C., et al. miR-34 cooperates with p53 in suppression of prostate cancer by joint regulation of stem cell compartment. Cell Rep 6 (2014), 1000–1007.
73. [73] Rokhlin, O.W., Scheinker, V.S., Taghiyev, A.F., Bumcrot, D., Glover, R.A., Cohen, M.B., MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol Ther 7 (2008), 1288–1296.
74. [74] Yamamura, S., Saini, S., Majid, S., et al. MicroRNA-34a suppresses malignant transformation by targeting c-Myc transcriptional complexes in human renal cell carcinoma. Carcinogenesis 33 (2012), 294–300.